Emerald Health

An Exceptional Team with a Unique Spin -- CFN Media

SEATTLE, WA--(Marketwired - Mar 27, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces an article discussing how Emerald Health Therapeutics Inc.'s (TSX VENTURE: EMH) exceptional management team and Board of Directors has taken a unique approach to the market by focusing on cannabinoid genetics.

Canada's cannabis industry could reach $22.6 billion over the coming years, according to Deloitte, with a retail market worth up to $8.7 billion. With only around 40 producers licensed by Health Canada thus far, there's a significant market opportunity for licensed producers to capitalize on this growth over time. Many licensed producers have already surpassed a half-billion dollar market capitalization, but there are also many smaller niche opportunities.

Assembling a World-Class Team
Emerald Health has built a world-class management team and Board of Directors that have carried out a combined $1+ billion in clinical trials and raise over $500 million in funding.

Executive Chairman Avtar Dhillon, MD, serves on the board of five public life science companies and led the turnaround of Inovio Pharmaceuticals Inc. from $10 million to a $1 billion company. CFO Sandra Pratt, CPA, CA, has also accumulated over 20 years of experience in accounting and finance with Angiotech Pharmaceuticals Inc., which grew into a company worth over $100 million.

President & CEO Bin Huang, PhD, MBA, has over 20 years of experience in life sciences including 15 years of serving as Chief Executive Officer. In terms of cannabis-specific experience, VP Production Traviss Graham has over 15 years of experience in cannabis production, processing, and product development, while VP R&D Frey Garabagi, PhD, has over 10 years of experience in plant molecular genetics and medical technologies.

Few producers in the space can lay claim to such a pharmaceutically qualified team, making Emerald better positioned than most to benefit from the opportunity in cannabinoid-based medicine.

Securing Government Funding
Emerald Health secured federal funding to characterize cannabis strains from the Canadian National Research Council's Industrial Research Assistance Program ("NRC-IRAP") in 2015.

The company was able to secure the funding with its rich collection of genetic materials, compelling research proposal, highly-credentialed team, and its proactive outreach to the NRC for support. In particular, the company proposed characterizing (or fingerprinting) mother plants, screening seeds to identify seeds with desirable cannabinoid/terpene profiles, and then developing those plants for individual patient needs.